1 / 17

Hyogo College of Medicine

2 nd International Conference on Hematology & Blood Disorders （ Sep. 29-Oct. 01, 2014 Baltimore, USA ）. Graft-versus-GVHD, a second transplantation from another donor for the rescue from refractory acute GVHD. The Hospital of Hyogo College of Medicine. Hyogo College of Medicine.

stevenmercado
Download Presentation

Hyogo College of Medicine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 2nd International Conference on Hematology & Blood Disorders（Sep. 29-Oct. 01, 2014 Baltimore, USA） Graft-versus-GVHD, a second transplantation from another donor for the rescue from refractory acute GVHD The Hospital of Hyogo College of Medicine Hyogo College of Medicine Kazuhiro Ikegame

  2. Concept of Graft-versus-GVHD (GvGVHD) Autoimmune GVHD joint skin Self-reactive lymphocytes Donor lymphocyte Graft-versus-Autoimmunity (GVA) liver muscle Graft-versus-GVHD (GvGVHD) nerve gut alloreactive cell therapy DNA

  3. Autologous PBSCT for severe GVHD mPSL tacrolimus MMF ATG MTX hemorrhagic cystitis FLU+CY+TBI diarrhea Plts(x106/l) WBC(x106/l) skin rash alloBMT autoPBSCT WBC 20 104 ALG 8mg/kg 15 103 TBI 2Gy 10 TT 10mg/kg 102 Plts 10 5 0 20 40 60 80 100 Days after transplantation BM relapse on day 144 after 2nd autoPBSCT Taniguchi Y, et al. Haematologica. 2003; 88.

  4. Case reports of autologous PBSCT for GVHD Bone Marrow Transplantation (2004) 34, 995–998

  5. AutoSCTfor GVHD (mouse model) 1st BMT ( b / d ) 2nd BMT ( b / k ) ( BDF1) (B6C3F1) BM 1×107 spleen 3×107 BM 1×107 spleen 3×107 2weeks Recipient ( b / k ） ( B6C3F1) TBI 0, 2, 3, 4, 5 Gy TBI 8.5Gy Taniguchi Y, et al. Exp Hematol. 2008; 36:1216.

  6. B6C3F1→(B6C3F1→B6C3F1) B6C3F1→(BDF1→B6C3F1) TBI 4Gy BDF1→B6C3F1 TBI 3Gy B6C3F1→(BDF1→B6C3F1) TBI 5Gy GVHD TBI toxicity GVHD BDF1→B6C3F1 2nd SCT B6C3F1→(BDF1→B6C3F1) TBI 3Gy GVHD TBI BDF1→B6C3F1 BDF1→B6C3F1 TBI 3Gy B6C3F1→(BDF1→B6C3F1) TBI 3Gy B6C3F1→(BDF1→B6C3F1) TBI 4Gy B6C3F1→(B6C3F1→B6C3F1)

  7. Problems of AutoSCT for GVHD 1) Difficult to engraft（GVH clones are rejecting clones） 2) Risk of relapse（Loss of GVL effect） Rejection BDF1 (b/d) lymphocytes b k b b k b d GVL No GVL d d B6C3F1 (b/k) stem cells b k b d k b k b B6C3F1 (b/k) normal tissue b B6C3F1 (b/k) leukemic cells GVHD k b B6C3F1 (b/k) leukemic cells

  8. Allogeneic is better than autologous for severe GVHD? 第17回クリニカルヘマトオンコロジー 5/14/2010

  9. AlloSCTfor GVHD (mouse model) 1st BMT ( b / d ) 2nd BMT ( b / s ) ( BDF1) (B6B10F1) BM 1×107 spleen 3×107 BM 1×107 spleen 3×107 1, 2, 3 weeks Recipient ( b / k ） ( B6C3F1) TBI 8.5Gy TBI 0, 2, 3, 4, 5 Gy

  10. T cell chimerism of 1st and 2nd donors after 2nd SCT 2nd donor chimerism TBI dose For 2nd SCT Improvement in GVHD score Experiment SCT sequence Day 7 Day 14 1 3Gy 47 ± 20 95 ± 3.4 + B6C3F1 → (BDF1→B6C3F1) ± b/k b/d b/k 2 B6C3F1 → (BDF1→B6C3F1) 4Gy 99 ± 0.8 99 ± 1.1 + b/k b/d b/k 3 B6B10F1 → (BDF1→B6C3F1) 3Gy 99 ± 0.9 99 ± 1.1 + b/s b/d b/k 4 B6B10F1 → (BDF1→B6C3F1) 0 25 ± 10 18 ± 18 - b/s b/d b/k 5 3Gy 2.6 ± 2.5 1.8 ± 3.6 - C3DF1 → (BDF1→B6C3F1) d/k b/d b/k 3Gy is not enough when GVHD clones are rejecting clones 6 DBA/2 → (BDF1→B6C3F1) 0 40 ± 7.1 25 ± 3.1 - d/d b/d b/k TBI is indispensable in homo-to-hetero(hybrid resistance?) 7 DBA/2 → (BDF1→B6C3F1) 3Gy 78 ± 8.6 96 ± 2.5 + d/d b/d b/k

  11. Human is more important than mouse?

  12. Graft-versus-GVHD Mouse model Clinical Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor. Taniguchi Y, et al. Exp Hematol. 2008. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation. Ikegame K, et al. Exp Hematol. 2011. Second SCT for refractory acute GVHD from another haploidentical donor (n=15 cases) Engraftment 11, rejection 4 OS@3yr 53% in engraftment cases, early death of GVHD in all rejected cases

  13. Representative regimen of GvGVHD day -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 PBSCT FLU 30mg/m2 ATGF 2mg/kg TBI 3Gy Tacrolimus civ (9-11ng/ml) mPSL 1mg/kg

  14. Change of GVHD stage along time course before and after GvGVHD in engrafted cases gut skin liver No. 1 0 -10 10 20 30 -10 0 10 20 30 -10 0 10 20 30 No. 4 0 0 -10 0 10 20 30 -10 10 20 30 -10 10 20 30 No. 5 0 0 0 -10 10 20 30 -10 10 20 30 -10 10 20 30 No. 6 0 0 0 -10 10 20 30 -10 10 20 30 -10 10 20 30 No. 8 0 0 0 -10 10 20 30 -10 10 20 30 -10 10 20 30 No. 9 -10 0 10 20 30 -10 0 10 20 30 -10 0 10 20 30

  15. Response and survival after GvGVHD engraftment Patients with complete response (%) rejection engraftment rejection

  16. Lineup of HCM(Acknowlegement) Comedical staffs of the ward (Coach) team effort Ward (clinical) Prof. Ogawa Nurses Doctors Kaida (FW) Taniguchi K (FW) Ishi (FW) Inoue (graduate student) Yoshihara (MF) Kato (graduate student) Ikegame (MF) PT Okada (CB) Tamaki (CB) pharmacists Fujioka (SB) Taniguchi Y (SB) Pain control team Clinical psychiatrists Soma (GK) Lab. (research)

More Related